Medical Marijuana Report

Medical marijuana market set for a sharp rise due to increased uptake

Medical marijuana is set to become a hot area in the pharmaceutical industry in the coming years. The use of cannabis-based medication has been a subject of debate for some time, but the merits of medical marijuana heavily outweigh the negatives.

Through GlobalData’s in-depth thematic research you will be able to strengthen your understanding of the medical marijuana market. Follow the US, France, Germany, Italy, Spain, UK, Canada, Israel, and Australia as they continue to invest in medical marijuana products and CBD oil. Due to this area being so new, the market will sharply rise at the CAGR of 81.3% between 2018 and 2025 reaching a value of $3.2bn.

  • What you will discover...
  • Epidiolex is used to treat refractory childhood-onset epilepsy and is expected to launch in 2020.
  • GW Pharma’s Sativex is approved for muscle spasticity in patients suffering from multiple sclerosis in Europe, and is currently at the pre-registration stage in the US.
  • Dravet syndrome and Lennox-Gastaut syndrome can cause hundreds of seizures a fortnight for sufferers; medical marijuana treatments focus on conditions such as these.

Be at the forefront of the medical marijuana market...

There are five approved medical marijuana treatments – Epidiolex, Marinol, Sativex, Nabilone and Syndros – in the countries discussed in this report (the US, France, Germany, Italy, Spain, the UK, Canada, Israel, and Australia).

Drug candidates Zygel (cannabidiol) and Lenabasum are being developed by US biopharmaceutical companies Zynerba Pharma and Corbus Pharma, respectively, and are expected to launch in the US and 5EU markets in 2021.

Magdalene Crabbe, Pharmaceutical Analyst at GlobalData, comments:

“Both Zygel and Lenabasum were granted fast track and orphan drug designation by the US Food and Drug Administration (FDA), and are expected to generate sales of $417m and $771m in 2025, respectively. Contributing to the high sales figures for these late-stage pipeline agents is the fact that Zygel and Lenabasum are both being developed to treat multiple disorders from a variety of therapy areas, including genetic disorders, musculoskeletal conditions, and autoimmune diseases.”

Take advantage of the infancy of this market and allow your company to get ahead of the competition in 2020 with our report, click ‘Buy Now’ to purchase this thematic research.

Buy This Report

Single user $ 7,995


Buy Now


reportstore@globaldata.com

+44 (0) 161 359 5813


Not ready to buy yet? Download more information on the report

I consent to GlobalData collecting my details provided via this form.

You are in control of the communications you receive from us and you can update your preferences anytime to make sure you are receiving information that matters to you. Please check our GlobalData Privacy Policy to see how we protect and manage your submitted data.